About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

GRASS (Grass MATA MPL Real-world Assessment Study) | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNCT07412990

GRASS (Grass MATA MPL Real-world Assessment Study)

Objective of this non-interventional study (NIS) is to collect data on the use of Grassmuno® in routine clinical practice.

Lead sponsor: Allergy Therapeutics•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Ralph Mösges, Univ. Prof. Dr. med. Dipl.-Ing

CONTACT

+49 172 2056 230 Ralph.Moesges@Uni-Koeln.de

Sponsors

Lead Sponsor

Allergy Therapeutics

Collaborators

Bencard Allergie GmbH
ClinCompetence Cologne GmbH

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•At the physician's discretion and based on the current Summary of Product Characteristics (SmPC), study participation may be offered to patients who
•are male and female patients
•are 18 years of age or older
•treated in accordance with the SmPC of Grassmuno® for IgE-mediated moderate to severe allergic rhinitis and/or rhinoconjunctivitis (without asthma or with well-controlled asthma) triggered by grass pollen.
•Patients will only be enrolled in the study after the treatment decision has been made

Exclusion Criteria

•At the physician's discretion, the study should not be offered to the following patients:
•Patients who are not sufficiently proficient in or do not adequately understand the German language, as this would prevent adequate comprehension of study-relevant documents.
•In addition, patients should not be included if any of the contraindications listed in the current Summary of Product Characteristics (SmPC) are present.

Related studies

COMPLETEDPhase 2

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

NCT04502966 · Allergic Rhinoconjunctivitis, Grass Pollen Allergy

A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment

NCT05560698 · Grass Pollen Allergy, Rhinoconjunctivitis

Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens

NCT04435678 · Birch Pollen Allergy, Grass Pollen Allergy, and more

COMPLETEDPhase 2

Phase II Study of Grass Pollen Allergy Vaccine BM32

NCT01538979 · Grass Pollen Allergy

Regulatory T-cells After Subcutaneous Immunotherapy

NCT01830673 · Grass Pollen Allergy, Specific Immunotherapy

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 20, 2026Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment1,000

Start dateMar 2026

Last updatedMar 20, 2026

Condition

Grass Pollen Allergy

Locations shown

Dr. Kasche

Hamburg

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 20, 2026Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions